Independence Blue Cross, Colorectal Cancer Alliance launch prevention program geared toward Black communities

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Fred Hutch researchers launch free online tool to assess CRC risk

Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.

January 09, 2026

Vol.52 No.1

Guest Editorial

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

Patients in Nepal experience substantial delays when accessing cancer care, study finds

Substantial delays are taking place across the cancer care pathway in Nepal, with many patients waiting months between first symptoms and treatment, according to an article by the International Agency for Research on Cancer and partners.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

Xilio Therapeutics announced data from its ongoing Phase II clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq) in patients with microsatellite stable metastatic colorectal cancer.

November 14, 2025

Vol.51 No.42

Podcast The Directors

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”

At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.

November 07, 2025

Vol.51 No.41

By Jacquelyn Cobb and Paul Goldberg

Independence Blue Cross, Colorectal Cancer Alliance launch prevention program geared toward Black communities

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Patients in Nepal experience substantial delays when accessing cancer care, study finds

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”

Renew today!

Subscriber content

Never miss an issue!

Login

Independence Blue Cross, Colorectal Cancer Alliance launch prevention program geared toward Black communities

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Patients in Nepal experience substantial delays when accessing cancer care, study finds

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery“This has always made our environment stronger, not weaker.”

Never miss an issue!

Login

The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery
“This has always made our environment stronger, not weaker.”